View More Recent Stories

Jun 25, 2015 07:00AM U.S. FDA Grants Priority Review for MM-398 New Drug Application
Jun 15, 2015 04:01PM Merrimack Pharmaceuticals Announces the Addition of John M. Dineen, Former CEO of GE Healthcare, to Its Board of Directors
Jun 11, 2015 05:00PM Merrimack Pharmaceuticals Announces Expansion of MM-398 (nal-IRI) Imaging Study to Patients with Metastatic Breast Cancer
Jun 1, 2015 04:12PM Merrimack Pharmaceuticals Announces Data from an Investigator-Sponsored Phase 1 Study Showing Acceptable Safety Profile for MM-398 in High-Grade Glioma
May 14, 2015 08:00AM Merrimack Pharmaceuticals Announces Presentations at the 2015 American Society of Clinical Oncology (ASCO) Annual Meeting
May 7, 2015 04:01PM Merrimack Pharmaceuticals Reports First Quarter 2015 Financial Results
May 5, 2015 08:00AM Merrimack Pharmaceuticals Announces Initiation of a Phase 2 Front-line Clinical Trial of MM-141 in Biomarker-Selected Patients with Metastatic Pancreatic Cancer
May 4, 2015 09:00AM Baxter Bioscience and Merrimack Pharmaceuticals Announce Filing for European Approval of MM-398, an Investigational Treatment for Post-Gemcitabine Metastatic Pancreatic Cancer
Apr 28, 2015 04:15PM Merrimack Pharmaceuticals Announces Timing of First Quarter 2015 Investor Conference Call and Presentation at Credit Suisse 2015 Antibody Conference
Apr 27, 2015 07:00AM Merrimack Pharmaceuticals and Baxter BioScience Announce Completion of New Drug Application Submission to U.S. FDA for MM-398 as a Treatment for Post-Gemcitabine Metastatic Pancreatic Cancer
Apr 21, 2015 08:00AM First-in-Human Phase 1 Trial of MM-141 Demonstrates Activity in Biomarker Positive Patients
Apr 20, 2015 04:01PM Merrimack Announces Final Clinical Results for MM-302 Phase 1 Study Demonstrating Robust Activity in Heavily Pre-Treated Patients with HER2-Positive Metastatic Breast Cancer
Mar 26, 2015 08:00AM Merrimack to Highlight Extensive Oncology Pipeline at the 2015 American Association for Cancer Research Annual Meeting
Feb 12, 2015 08:00AM Merrimack Pharmaceuticals Announces Timing of Fourth Quarter 2014 Investor Conference Call
Jan 22, 2015 05:00PM Merrimack Pharmaceuticals Names Birgit M. Schoeberl, Ph.D. as Head of Discovery Division and Announces the Addition of Ulrik B. Nielsen, Ph.D. to Its Board of Directors
Dec 17, 2014 08:00AM Merrimack Pharmaceuticals Announces the Addition of Russell T. Ray to Its Board of Directors
Dec 12, 2014 08:00AM Merrimack Pharmaceuticals Presents Research on Innovative Pipeline for Patients With Breast Cancer at the 2014 San Antonio Breast Cancer Symposium
Nov 10, 2014 04:01PM Merrimack Pharmaceuticals Reports Third Quarter 2014 Financial Results
Nov 5, 2014 09:00AM FDA Grants Orphan Drug Designation to Merrimack Pharmaceuticals' MM-141 for the Treatment of Pancreatic Cancer
Sep 30, 2014 08:00AM Merrimack Pharmaceuticals Presents Additional Phase 2 Biomarker Data Further Strengthening the Finding That MM-121 Increases Progression Free Survival in Patients With Biomarker Positive Metastatic Br
View More Recent Stories